Study of Gene Activity in Fat and Muscle in Diabetics and Healthy Controls
Primary Purpose
Healthy, Type 2 Diabetes, Endotoxemia
Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Escherichia Coli Endotoxin
Sponsored by
About this trial
This is an interventional prevention trial for Healthy focused on measuring Low-grade inflammation, insulin resistance, Metabolism, Type 2 diabetes, Endotoxemia, Fat tissue, Muscle tissue, RT-PCR
Eligibility Criteria
Inclusion Criteria:
- Healthy
- Type 2 diabetes
Exclusion Criteria:
- Heart failure
- Lung disease
- Anti-coagulation treatment
Sites / Locations
- Centre of Inflammaiton and Metabolism, Rigshospitalet
Outcomes
Primary Outcome Measures
Gene expression evaluated by measuring mRNA via RT-PCR. Plasma cytokine content, PLasma PAI-1 content, endotoxemia score
Secondary Outcome Measures
Mean Arterial Pressure, heart rate, Temperature,
Full Information
NCT ID
NCT00412906
First Posted
December 18, 2006
Last Updated
May 20, 2008
Sponsor
Rigshospitalet, Denmark
1. Study Identification
Unique Protocol Identification Number
NCT00412906
Brief Title
Study of Gene Activity in Fat and Muscle in Diabetics and Healthy Controls
Official Title
Study of Gene Expression in Fat and Muscle Tissue in Type 2 Diabetics and Healthy Controls During Experimental Endotoxemia
Study Type
Interventional
2. Study Status
Record Verification Date
May 2008
Overall Recruitment Status
Completed
Study Start Date
November 2006 (undefined)
Primary Completion Date
April 2008 (Actual)
Study Completion Date
April 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Rigshospitalet, Denmark
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of the present protocol is to study gene activity in fat and muscle tissue in type 2 diabetics and healthy volunteers after injection of E. coli endotoxin.We hereby hope to gain insight in some mechanisms behind the association between inflammation and insulin resistance.
Detailed Description
Numerous studies have shown an association between low-grade inflammation and insulin-resistance in type 2 diabetics. It is also well-known that septic patients often develop insulin-resistance. The pathogenetic mechanisms behind the association between inflammation and insulin-resistance is not fully understood.
In this study we create an experimental inflammation by giving E. coli endotoxin 0,3 ng/kg iv to type 2 diabetics and healthy controls. Muscle biopsies are taken at 0, 2, 4 and 6 hours after injection, while fat biopsies are taken 0, 2, 4, 6 and 8 hours after endotoxin. mRNA for adiponectin, leptin, PPAR-gamma, PGC-1, PAI-1 and cytokines in tissue is later measured by RT-PCR.
Blood samples are drawn on an hourly basis until 8 hours after endotoxin injection for common biochemical analyses including white blood cell count. Plasma is spared and later analyzed for cytokines, PAI-1 and VCAM-1/ICAM-1.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy, Type 2 Diabetes, Endotoxemia
Keywords
Low-grade inflammation, insulin resistance, Metabolism, Type 2 diabetes, Endotoxemia, Fat tissue, Muscle tissue, RT-PCR
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
48 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Escherichia Coli Endotoxin
Primary Outcome Measure Information:
Title
Gene expression evaluated by measuring mRNA via RT-PCR. Plasma cytokine content, PLasma PAI-1 content, endotoxemia score
Secondary Outcome Measure Information:
Title
Mean Arterial Pressure, heart rate, Temperature,
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy
Type 2 diabetes
Exclusion Criteria:
Heart failure
Lung disease
Anti-coagulation treatment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anne Sofie Andreasen, MD
Organizational Affiliation
Rogshospitalet, Denmark
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre of Inflammaiton and Metabolism, Rigshospitalet
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark
12. IPD Sharing Statement
Citations:
PubMed Identifier
21931634
Citation
Andreasen AS, Kelly M, Berg RM, Moller K, Pedersen BK. Type 2 diabetes is associated with altered NF-kappaB DNA binding activity, JNK phosphorylation, and AMPK phosphorylation in skeletal muscle after LPS. PLoS One. 2011;6(9):e23999. doi: 10.1371/journal.pone.0023999. Epub 2011 Sep 13.
Results Reference
derived
Learn more about this trial
Study of Gene Activity in Fat and Muscle in Diabetics and Healthy Controls
We'll reach out to this number within 24 hrs